Paysign, Inc.

Paysign, Inc. (PAYS) Market Cap

Paysign, Inc. has a market capitalization of $500.9M.

Price: $8.96

-0.20 (-2.18%)

Market Cap: 500.92M

NASDAQ · time unavailable

CEO: Mark Newcomer

Sector: Industrials

Industry: Specialty Business Services

IPO Date: 2007-10-10

Website: https://www.paysign.com

Paysign, Inc. (PAYS) - Company Information

Market Cap: 500.92M|Sector: Industrials

Company Profile

Paysign, Inc. provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card and software solutions. It also operates a customer service center; and offers a communication suite, including mobile app, two-way SMS, text alerts, and cardholder web portal. The company markets its prepaid card solutions under the Paysign brand. It serves companies and municipalities that require payment solutions for rewards, rebates, payment assistance, and other payments to their customers, employees, agents, and others. Paysign, Inc. was founded in 2001 and is headquartered in Henderson, Nevada.

Analyst Sentiment

90%
Strong Buy

From 5 Active Polls

1Y Forecast: $9.00

▲ +0.4% Potential Upside

Consensus Target Metrics

Low Bound

$9

Median

$9

High Bound

$9

Average

$9

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$9.00
▲ +0.45% Upside
Low Target
$9.00
0% Risk
Median Target
$9.00
0% Mid
High Target
$9.00
0% Max
Consensus
Buy
5 / 8 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)501325284345390114161196209
Enterprise Value ($M)486311277343381110153189181
Price to Earnings Ratio (P/E)46.9814.7552.1338.9270.3110.6029.3834.1174.81
Price/Earnings-to-Growth Ratio (PEG)0.649.722.9527.230.5512.805.298.64
Price to Sales Ratio (P/S)5.4811.6112.4715.9620.476.1110.3012.8614.61
Price to Book Ratio (P/B)8.995.925.857.539.252.895.286.887.80
Price to Free Cash Flow Ratio (P/FCF)7.1619.026.1175.43213.21-13.4013.49-8.6811.51
Enterprise Value to Sales (EV/Sales)11.0912.1615.8919.995.899.7912.3812.64
Enterprise Value to EBITDA (EV/EBITDA)20.8430.7658.8578.6291.6221.6952.0161.8176.18
Debt to Equity Ratio-0.630.110.290.130.060.070.100.110.12

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PAYSIGN INC (PAYS) — Investment Overview

🧩 Business Model Overview

PAYSIGN is a B2B2C payments provider centered on prepaid and related card-based payment programs. The operating model typically follows a platform-and-partners structure: PAYSIGN enables issuance and processing of prepaid products (cards and digital variants), supports KYC/AML program operations, manages transaction processing and settlement workflows, and earns consideration through transaction-linked economics and program/processing services.

Customer “stickiness” comes from the integration layer (corporate or institutional program onboarding, compliance tooling, payout/disbursement workflows) and the ongoing operational workflow (reloads, card lifecycle management, dispute/chargeback handling, and reconciliation).

💰 Revenue Streams & Monetisation Model

  • Transaction-linked income: fees and consideration tied to card usage (processing, interchange-like economics depending on arrangement, and other transaction fees).
  • FX/foreign spend economics: where cross-border or multi-currency prepaid products exist, profitability is driven by spreads and operational FX management (net of hedging/settlement frictions).
  • Program and service fees: B2B revenue from managing prepaid programs for corporates/partners (often more recurring than pure transaction volume).
  • Ancillary card economics: potential income from activation, replacement, and other card lifecycle events (materiality varies by program mix and geography).

Margin drivers are primarily (1) the take rate on transactions (fees net of partner costs), (2) FX spread durability where applicable, and (3) operating leverage as transaction volumes scale against fixed compliance and technology costs.

🧠 Competitive Advantages & Market Positioning

PAYSIGN’s moat is best described as switching costs plus regulatory/compliance embeddedness rather than classic consumer network effects.

  • Switching costs (program integration & operational lock-in): corporate/partner onboarding for prepaid programs involves KYC/KYB workflows, settlement and reconciliation processes, card lifecycle operations, and dispute management. Replacement vendors typically require re-integration and re-certification of operational processes.
  • Regulatory and compliance track record: prepaid issuance and related processing require robust AML/KYC controls and monitoring. This raises the bar for new entrants and increases the compliance cost of switching.
  • Economies of processing scale: as volumes increase, unit processing costs and risk/compliance overhead can decline, supporting better contribution margins.

Competitive benchmarking (focus and differentiation):

  • Euronet Worldwide: broad payments platform footprint (including card processing and other payment services). PAYSIGN’s emphasis is more concentrated on prepaid and partner-enabled program models rather than a more diversified processing-led mix.
  • Nium (formerly InstaReM/linked remittance offerings): stronger focus on cross-border payments and money transfer rails. PAYSIGN’s positioning centers on card-based prepaid mechanisms and program-based distribution.
  • Cashfree / Razorpay (India payments ecosystem peers): oriented toward merchant acquiring and platform-enabled payment acceptance. PAYSIGN is less centered on merchant acquiring and more on prepaid program issuance and transaction processing through partner channels.

In short, while competitors may compete across payment categories, PAYSIGN’s defensibility is strongest where prepaid program integration, compliance operations, and ongoing partner management are central.

🚀 Multi-Year Growth Drivers

  • Shift toward cashless and card-based payment instruments: prepaid products provide a pragmatic route for underbanked/limited-bankability user segments and controlled-spend use cases.
  • Corporate payouts and employee benefit disbursements: prepaid rails can support structured spending programs, reimbursements, and controlled budgets—creating repeatable B2B demand.
  • Cross-border commerce and travel spend: growth in international e-commerce and travel sustains demand for multi-currency prepaid solutions and partner distribution.
  • Partner channel expansion: PAYSIGN can scale through additional issuance/processing relationships with banks, fintech partners, and distribution networks without proportionate fixed-cost increases.
  • Digital product migration: transition from physical to digital card experiences and embedded prepaid/virtual card use can enhance transaction frequency and engagement.

⚠ Risk Factors to Monitor

  • Regulatory risk: prepaid card frameworks, KYC/AML expectations, and operational requirements can change across jurisdictions, affecting product economics and compliance costs.
  • Partner/bank concentration risk: reliance on issuing/settlement partners can shift economics if partner terms or routing controls change.
  • Competitive pricing pressure: payments platforms can face take-rate compression as competitors scale and bid for partner programs.
  • Fraud, chargebacks, and risk management: prepaid programs can face elevated fraud attempts relative to some payment types; loss rates directly impact profitability.
  • FX and settlement volatility: where multi-currency products are material, FX spreads, hedging effectiveness, and settlement timing can affect margins.
  • Technology and operational resilience: payments processing requires continuous uptime, strong cybersecurity controls, and disciplined reconciliation to avoid revenue leakage.

📊 Valuation & Market View

Markets typically value payments and transaction platforms using a blend of Revenue multiple (P/S) and cash flow/earnings metrics (EV/EBITDA), with higher multiples when businesses demonstrate durable unit economics and scalable infrastructure.

Key valuation drivers that influence the multiple include: (1) transaction growth with stable or expanding take rate, (2) demonstrable operating leverage, (3) controllable credit/fraud loss dynamics, and (4) evidence that regulatory capital/compliance overhead is not structurally rising faster than contribution margins.

🔍 Investment Takeaway

PAYSIGN’s long-term thesis rests on switching costs created by prepaid program integration and compliance operations, supported by processing-scale efficiencies and recurring elements of partner program management. The investment case is strongest when the company maintains competitive take rates, improves operating leverage, and sustains disciplined risk and compliance execution—while managing regulatory, partner, and pricing pressures typical to prepaid/payment ecosystems.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for PAYS.

businesswire.com2026-07-14

Paysign to Host Second Quarter 2026 Earnings Call

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, will discuss second quarter 2026 earnings at 5:00 p.m. Eastern time on Wednesday, August 5, 2026. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.68.

gurufocus.com2026-06-02

Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026

Paysign, Inc. (NASDAQ: [url="]PAYS[/url]), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platfo

businesswire.com2026-06-02

Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026.

gurufocus.com2026-05-27

Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference

Paysign, Inc. (NASDAQ: [url="]PAYS[/url]), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platfo

businesswire.com2026-05-27

Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference.

seekingalpha.com2026-05-13

Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript

Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript

fool.com2026-05-13

Breakfast News: Wix.com Pins Hopes on AI Tools

Wix.com revenue growth continues, PaySign beats Q1 management guidance, and more

marketbeat.com2026-05-12

Paysign Q1 Earnings Call Highlights

Paysign NASDAQ: PAYS reported what executives described as the strongest start to a year in the company's history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and profitability expanding sharply as its patient affordability business became its largest revenue contributor.

businesswire.com2026-05-12

Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026.

businesswire.com2026-04-15

Paysign to Host First Quarter 2026 Earnings Call

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host First Quarter 2026 Earnings Call.

seekingalpha.com2026-04-09

Paysign: The Market Is Finally Repricing A Pharma Margin Story

Paysign is evolving beyond a niche prepaid card processor, with patient affordability now driving higher-margin growth. 2025 results highlight a 40.5% revenue increase to $82M, with pharma revenue surging to $33.9M and gross margin expanding to 59.4%. PAYS trades above peer sales multiples, reflecting its shift to a high-value workflow business, while price-to-cash flow remains attractive if cash conversion holds.

seekingalpha.com2026-03-31

Paysign Is On A Roll

Paysign remains a buy, supported by strong performance in both Plasma Centers and hypergrowth in Patient Affordability. PAYS's Plasma Center segment holds a 50% market share, adding 115 new centers in FY25, despite revenue per center declining due to plasma surplus. That surplus can disappear, and the Plasma segment can benefit from the BECS, generating high-margin SaaS subscription revenue.

defenseworld.net2026-03-26

Paysign Q4 Earnings Call Highlights

Paysign (NASDAQ: PAYS) reported fourth-quarter and full-year 2025 results that management said showed "continued strength and exceptional growth" across key metrics, driven primarily by rapid expansion in its patient affordability platform and improving operating leverage. Full-year 2025 results and margin improvement For full-year 2025, the company said revenue increased 40.5% to $82.0 million. Net income rose

fool.com2026-03-25

Why Paysign Stock Is Skyrocketing Today

Paysign posted Q4 earnings that were in line with Wall Street's target and sales that beat expectations. The company's forward guidance is spurring huge gains for the stock.

seekingalpha.com2026-03-25

Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript

Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Q1’26 Revenue was $28.0M and Net Income was $5.4M (EPS: $0.09 diluted). YoY, Revenue rose +50.6% (from $18.6M in Q1’25) and Net Income rose +110.2% (from $2.6M). QoQ, Revenue increased +23.1% (from $22.8M in Q4’25) while Net Income jumped +299.6% (from $1.4M). Profitability improved versus both recent quarters, with gross margin expanding from 47.9% (Q4’25) to 64.98% (Q1’26) and net margin expanding to 19.40% (up from 5.99% in Q4’25 and above Q1’25’s 13.91%). Cash flow data appear inconsistent across quarters (e.g., operating cash flow is shown as 0 in Q1’26, and balance-sheet cash jumps due to FX effects), so operating cash flow quality for the quarter is hard to validate from the provided fields. Balance sheet resilience looks strong: total assets grew to $312.7M from $276.3M in Q4’25, while equity increased to $55.0M from $48.5M, with net debt remaining negative (net cash position). There were no dividends, and no buybacks are shown; shareholder returns therefore likely rely on price momentum. PAYS is up +200.96% over 1 year, which should materially support total shareholder returns. Analyst sentiment/valuation: consensus price target is $9 versus the latest price of $6.29 (upside implied ~43%)."

Revenue Growth

Strong

Q1’26 Revenue of $28.0M grew +50.6% YoY (vs $18.6M in Q1’25) and +23.1% QoQ (vs $22.8M in Q4’25), with a clear accelerating run-rate across the last four quarters.

Profitability

Good

Margins expanded meaningfully: gross margin rose to 64.98% in Q1’26 from 47.96% (Q4’25) and net margin to 19.40% from 5.99% (Q4’25). Operating income margin improved to 23.78%.

Cash Flow Quality

Fair

Net Income increased sharply, but operating cash flow is reported as 0 in Q1’26 and free cash flow is 0, while cash changes show large FX effects. Based on provided fields, cash conversion for the quarter is uncertain.

Leverage & Balance Sheet

Good

Strong balance sheet: equity increased to $55.0M (from $48.5M in Q4’25) and net debt remains negative (net cash position). Total assets grew to $312.7M.

Shareholder Returns

Strong

Price momentum is very strong: +200.96% 1Y. No dividends or buybacks are shown in the cash flow, so total return is likely driven primarily by capital appreciation.

Analyst Sentiment & Valuation

Positive

Consensus price target is $9 vs $6.29 last price, implying ~43% upside. Valuation multiples appear elevated, but the recent earnings/margin acceleration provides some support.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

PAYS delivered an outsized Q1: revenue +50.8% YoY to $28M, operating margin expanded to 23.8% (+1,040 bps), and adjusted EBITDA grew +113% to $10.6M (37.8% margin, +1,110 bps). The key driver is patient affordability momentum—$15.7M revenue (+81.9%), ~49% higher process claims, and nearly $540M in patient assistance—causing pharma to overtake plasma as the largest revenue contributor. Management also maintained FY2026 guidance and signaled stronger confidence toward the upper end, with program counts expected to rise to 147–150 by end of Q2 and plasma centers to step down to 555–560 after a customer closure of 19 underperformers. Q&A clarified that plasma revenue should still grow sequentially despite center declines, due to cardholder transitions and improving loads. Risks are mainly tax-rate volatility, center churn from customer efficiency moves, and seasonality-driven mix effects. Sentiment is positive given leverage and pipeline visibility.

AI IconGrowth Catalysts

  • Patient affordability revenue +82% YoY to $15.7M; claim volume ~49% higher YoY and nearly $540M in financial assistance to patients in Q1
  • Operating leverage: operating margin 23.8% vs 13.4% prior-year (+1,040 bps) and operating income conversion of ~$9.4M incremental revenue into ~$4.2M operating income
  • Pharma surpasses plasma as largest revenue contributor for the first time in the quarter (Pharma $15.7M vs Plasma $11.7M)
  • New patient affordability program additions: launched 4 new programs in Q1; total active programs 135 exiting Q1 (with 55+ net program additions expected in 2026 guidance trajectory)

Business Development

  • Assembia Specialty Pharmacy Summit ASX 26 (Las Vegas): >50 meetings over 3 days and closed new business on site; used to shape commercial roadmap for 2026
  • Targeting 135 active programs in patient affordability and on-track >55 net program additions launched in 2025 (pipeline carryover into 2026)
  • Plasma ecosystem discussions (International Plasma Protein Congress in Milan, Italy): progress toward direct integration with plasmapheresis device manufacturers and conversations with plasma collection companies across U.S./Europe/Asia

AI IconFinancial Highlights

  • Total revenue: $28.0M, +50.8% YoY; exceeded March guidance high end ($27.0M–$27.5M)
  • Net income: $5.4M, +110% YoY; EPS $0.09 per diluted share vs $0.05 prior year
  • Adjusted EBITDA: $10.6M, +113% YoY; adjusted EBITDA margin 37.8% vs 26.7% (+1,110 bps)
  • Operating margin: 23.8% vs 13.4% (+1,040 bps); gross margin 65.0% vs 62.9% (+210 bps)
  • Tax rate: effective tax rate 27.2% vs 20.5% prior year; higher rate driven by discrete item adjustments tied to stock-price increase at March 31, 2026 reducing stock-based compensation tax benefit
  • Plasma revenue: $11.7M, +25% YoY; center-level: avg monthly revenue per center $6,671 vs $6,517, and avg loads per center up YoY for first time since 2024
  • Pharma revenue: $15.7M, +81.9% YoY; process claims +~49% YoY; mix shift supported gross margin expansion

AI IconCapital Funding

  • Unrestricted cash: $20.5M at quarter end; unrestricted cash described as ~“$21 million” in Q&A
  • Bank debt: 0
  • Restricted cash: $159M, up $15M, primarily customer program deposits for Plasma and Pharma plus increase in funds on card
  • No share repurchases during Q1 2026

AI IconStrategy & Ops

  • Patient affordability technology: dynamic business rules delivering economic value for pharmaceutical clients, including navigating co-pay maximizer and accumulator programs
  • Q1 pharma operational constraint: plan year transitions/formulary changes/deductible resets noted as typical; management cites pipeline robustness despite operational constraint
  • Plasma network optimization: customer closed 19 underperforming centers in early May; company expects plasma centers decline to 555–560 from 573 at quarter end (with some new centers opening)
  • Plasma center churn detail: exited Q1 with 573 centers, +89 YoY but -22 vs end of 2025 due to sale/closure of low-performing centers to collectors not using Paysign services
  • SaaS/app integration initiatives: direct integration to plasmapheresis device discussed to eliminate manual steps and reduce friction/implementation burden for collection centers
  • Guidance confidence operational bandwidth: systems described as high availability/high demand; confidence to scale via hiring on account management and IT readiness

AI IconMarket Outlook

  • FY2026 revenue guidance maintained/upward confidence: $106.5M–$110.5M (30%–35% YoY growth), gross profit margins 60%–62%
  • FY2026 profitability guidance maintained: net income $13M–$16M (EPS $0.21–$0.26 diluted); adjusted EBITDA $30M–$33M (EPS $0.49–$0.53 diluted)
  • Active patient affordability programs: 141 active as of call; exit Q2 target 147–150 active programs
  • Plasma centers: expect end of Q2 555–560 centers (after May 5 closure of 19 centers) and management expects plasma revenue to grow sequentially and throughout the year
  • Active programs milestone: active programs expected to exit Q1 at 135 and advance toward 147–150 by end of Q2 (per CFO) and continue pipeline to exceed 55 net program additions launched in 2025

AI IconRisks & Headwinds

  • Effective tax rate elevated to 27.2% vs 20.5% due to discrete adjustments related to stock-based compensation tax benefit—could affect quarter-to-quarter earnings variability
  • Plasma center count variability from customer consolidations/closures (19 underperforming centers closed by a customer; 573 centers exiting Q1 and guidance of decline to 555–560 in Q2)
  • Operational seasonality: pharma typically highest in Q1 due to deductible resets; plasma typically softest in Q1 and builds through year—requires margin management across mix shift
  • Concentration/competitive risk: management indicated one customer sold all centers to a competing provider impacting center guidance (Q1 exit centers below guidance of 589)

Q&A: Analyst Interest

  • Pipeline durability: Management explained confidence in exceeding 55 net program additions by citing a ~50/50 mix of entirely new client programs vs growth within existing manufacturer clients, with no single inflection event. They emphasized scaling from a larger client base, ongoing account growth, and continuous selling.
  • Plasma guidance mechanics: Analysts asked whether center declines imply a big ramp in H2. CFO responded plasma revenue should rise sequentially and grow through the year; sold/consolidated centers were underperforming “garbage” sites. Cardholders transition nearby, and management pointed to YoY load recovery post-2024 inventory overhang.
  • SaaS/app monetization & regulatory status: Analyst asked if the app is live and FDA-approved. CEO said discussions with the FDA are ongoing; current status is that revenues are not being generated from the SaaS/app yet. Additional targets for non-pharmaceutical business were acknowledged but not disclosed.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PAYS Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for PAYS.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (PAYS)

© 2026 Stock Market Info — Paysign, Inc. (PAYS) Financial Profile